Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 1.14
SCMP's Cash to Debt is ranked higher than
62% of the 750 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.39 vs. SCMP: 1.14 )
SCMP' s 10-Year Cash to Debt Range
Min: 1.1   Max: No Debt
Current: 1.14

Equity to Asset 0.43
SCMP's Equity to Asset is ranked higher than
51% of the 712 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.60 vs. SCMP: 0.43 )
SCMP' s 10-Year Equity to Asset Range
Min: -0.51   Max: 0.86
Current: 0.43

-0.51
0.86
Interest Coverage 4.86
SCMP's Interest Coverage is ranked lower than
51% of the 460 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 88.77 vs. SCMP: 4.86 )
SCMP' s 10-Year Interest Coverage Range
Min: 3.55   Max: 9999.99
Current: 4.86

3.55
9999.99
F-Score: 5
Z-Score: 3.46
M-Score: -2.00
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 10.26
SCMP's Operating margin (%) is ranked higher than
75% of the 710 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.34 vs. SCMP: 10.26 )
SCMP' s 10-Year Operating margin (%) Range
Min: -903.97   Max: 28.03
Current: 10.26

-903.97
28.03
Net-margin (%) 7.16
SCMP's Net-margin (%) is ranked higher than
71% of the 710 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.48 vs. SCMP: 7.16 )
SCMP' s 10-Year Net-margin (%) Range
Min: -906.55   Max: 41.39
Current: 7.16

-906.55
41.39
ROE (%) 11.04
SCMP's ROE (%) is ranked higher than
84% of the 713 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.00 vs. SCMP: 11.04 )
SCMP' s 10-Year ROE (%) Range
Min: -374.69   Max: 56.58
Current: 11.04

-374.69
56.58
ROA (%) 4.69
SCMP's ROA (%) is ranked higher than
74% of the 742 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.94 vs. SCMP: 4.69 )
SCMP' s 10-Year ROA (%) Range
Min: -109.69   Max: 32.5
Current: 4.69

-109.69
32.5
ROC (Joel Greenblatt) (%) 23.77
SCMP's ROC (Joel Greenblatt) (%) is ranked higher than
82% of the 732 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 14.50 vs. SCMP: 23.77 )
SCMP' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -9750.25   Max: 4304.08
Current: 23.77

-9750.25
4304.08
Revenue Growth (%) 12.50
SCMP's Revenue Growth (%) is ranked higher than
77% of the 552 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.10 vs. SCMP: 12.50 )
SCMP' s 10-Year Revenue Growth (%) Range
Min: -21.1   Max: 127
Current: 12.5

-21.1
127
» SCMP's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2013

SCMP Guru Trades in Q1 2013

Steven Cohen 21,583 sh (New)
Jim Simons 208,200 sh (+12.24%)
» More
Q2 2013

SCMP Guru Trades in Q2 2013

Jim Simons 235,000 sh (+12.87%)
Steven Cohen Sold Out
» More
Q3 2013

SCMP Guru Trades in Q3 2013

Jim Simons 127,800 sh (-45.62%)
» More
Q4 2013

SCMP Guru Trades in Q4 2013

Jim Simons 36,000 sh (-71.83%)
» More
» Details

Insider Trades

Latest Guru Trades with SCMP



No Insider Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Top Ranked Articles about Sucampo Pharmaceuticals, Inc.

Weekly CEO Sells Highlight: Sucampo Pharmaceuticals Inc, Family Dollar Stores Inc, Nike Inc, Halliburton Company
According to GuruFocus Insider Data, these are the largest CEO sales during the past week: Sucampo Pharmaceuticals Inc., Family Dollar Stores Inc., Nike Inc. and Halliburton Company. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 48.00
SCMP's P/E(ttm) is ranked lower than
52% of the 528 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 25.60 vs. SCMP: 48.00 )
SCMP' s 10-Year P/E(ttm) Range
Min: 5.44   Max: 115.73
Current: 48

5.44
115.73
P/B 4.94
SCMP's P/B is ranked lower than
53% of the 700 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.84 vs. SCMP: 4.94 )
SCMP' s 10-Year P/B Range
Min: 0.97   Max: 9.99
Current: 4.94

0.97
9.99
P/S 3.21
SCMP's P/S is ranked higher than
50% of the 722 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.99 vs. SCMP: 3.21 )
SCMP' s 10-Year P/S Range
Min: 1.2   Max: 6.98
Current: 3.21

1.2
6.98
EV-to-EBIT 31.59
SCMP's EV-to-EBIT is ranked lower than
53% of the 593 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 19.45 vs. SCMP: 31.59 )
SCMP' s 10-Year EV-to-EBIT Range
Min: 0.8   Max: 66.7
Current: 31.59

0.8
66.7
Shiller P/E 74.71
SCMP's Shiller P/E is ranked lower than
61% of the 362 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 25.59 vs. SCMP: 74.71 )
SCMP' s 10-Year Shiller P/E Range
Min: 4.62   Max: 115.44
Current: 74.71

4.62
115.44

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 5.55
SCMP's Price/Tangible Book is ranked lower than
56% of the 629 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.10 vs. SCMP: 5.55 )
SCMP' s 10-Year Price/Tangible Book Range
Min: 1.16   Max: 9.54
Current: 5.55

1.16
9.54
Price/DCF (Projected) 4.13
SCMP's Price/DCF (Projected) is ranked lower than
59% of the 346 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.70 vs. SCMP: 4.13 )
SCMP' s 10-Year Price/DCF (Projected) Range
Min: 1.3   Max: 5.73
Current: 4.13

1.3
5.73
Price/Median PS Value 1.07
SCMP's Price/Median PS Value is ranked higher than
58% of the 665 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.10 vs. SCMP: 1.07 )
SCMP' s 10-Year Price/Median PS Value Range
Min: 0.72   Max: 2.65
Current: 1.07

0.72
2.65
Price/Graham Number 3.33
SCMP's Price/Graham Number is ranked lower than
57% of the 461 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.20 vs. SCMP: 3.33 )
SCMP' s 10-Year Price/Graham Number Range
Min: 0.95   Max: 5.14
Current: 3.33

0.95
5.14
Earnings Yield (Greenblatt) 3.20
SCMP's Earnings Yield (Greenblatt) is ranked higher than
55% of the 595 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.80 vs. SCMP: 3.20 )
SCMP' s 10-Year Earnings Yield (Greenblatt) Range
Min: 1.5   Max: 119.5
Current: 3.2

1.5
119.5
Forward Rate of Return (Yacktman) 0.76
SCMP's Forward Rate of Return (Yacktman) is ranked higher than
70% of the 532 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.45 vs. SCMP: 0.76 )
SCMP' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 0.4   Max: 2.4
Current: 0.76

0.4
2.4

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:TKPYY, TEVA, AGN, FRX, MRX » details
Traded in other countries:R3A.Germany
Sucampo Pharmaceuticals, Inc., is a biopharmaceutical company focused on the discovery, development and commercialization of proprietary drugs based on prostones, a class of compounds derived from functional fatty acids that occur naturally in the human body. Sucampo is focused on developing prostones for the treatment of gastrointestinal, respiratory, vascular and central nervous system diseases and disorders for which there are unmet or underserved medical needs and commercial potential. The therapeutic potential of prostones was first identified by one of the company's founders. Two prostone-based products have received marketing approval: Amitiza for the treatment of chronic idiopathic constipation in adults and irritable bowel syndrome with constipation in adult women and Rescula for the treatment of glaucoma. Sucampo is mainly responsible for Amitiza research and development efforts and are the holder of the new drug application. Takeda is mainly responsible for the marketing and commercialization of Amitiza in the United States and Canada and markets Amitiza to office-based specialty physicians and primary care physicians in the United States and funds a portion of the research and development activities. Sucampo is currently pursuing marketing approval for Amitiza for opioid-induced bowel dysfunction in patients with non-malignant pain, a constipation-related gastrointestinal indication. Opioid pain relievers are prescribed for patients with chronic and acute pain, many of whom also develop opioid-induced bowel dysfunction. Sucampo is developing other prostone-based compounds for the treatment of a range of diseases. The most advanced of these programs are: Cobiprostone is currently in a phase 2 clinical trial for the prevention of ulcers induced by non-steroidal anti-inflammatory drugs. SPI-017 is being researched as a treatment of peripheral arterial and vascular disease and central nervous system disorders. Sucampo is developing the prostone compound cobiprostone for oral administration to treat various gastrointestinal and liver disorders, including NSAID-induced ulcers and portal hypertension.

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Hide